产品说明书

Empirical Formula

Print
Chemical Structure| 492-27-3 同义名 : 犬尿喹啉酸 ;Quinurenic acid;Kynurenic acid;Kynuronic acid;Kynurenate
CAS号 : 492-27-3
货号 : A141971
分子式 : C10H7NO3
纯度 : 97%
分子量 : 189.167
MDL号 : MFCD00149476
存储条件：

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 8 mg/mL(42.29 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

0.1 M NaOH: 10 mg/mL(52.86 mM)，配合低频超声，并调节pH至9
动物实验配方：
生物活性
靶点

  • NMDA receptor
描述 Kynurenic acid (KYNA) is an endogenous antagonist of glutamate in the central nervous system. It is most active as an antagonist at receptors sensitive to N‐methyl‐D‐aspartate (NMDA) which regulate neuronal excitability and plasticity, brain development and behaviour[3]. Peripheral administration of kynurenic acid, at a dose that caused plasma levels to increase 430-fold, resulted in only 4-fold increases in striatal ECF(extracellular fluid) concentrations[4]. KYNA has a significant protective effect on liver injury induced by thioacetamide (TAA)[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03557684 Depression Early Phase 1 Recruiting July 31, 2020 United States, California ... 展开 >> UCLA Cousins Center for Psychoneuroimmunology Recruiting Los Angeles, California, United States, 90095 Contact: Gracie Pineda    310-825-8425    grpineda@g.ucla.edu    Principal Investigator: Joshua H Cho, MD, PhD 收起 <<
NCT00573300 - Completed - United States, Massachusetts ... 展开 >> Freedom Trail Clinic Boston, Massachusetts, United States, 02114 收起 <<
NCT02234752 Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 << Phase 2 Terminated(Funding no longer a... 展开 >>vailable and PI no longer working at the institution) 收起 << - United States, Maryland ... 展开 >> Sheppard Pratt Health System Baltimore, Maryland, United States, 21204 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

5.29mL

1.06mL

0.53mL

26.43mL

5.29mL

2.64mL

52.86mL

10.57mL

5.29mL
参考文献

[1]Sekine A, Okamoto M, et al. Amino acids inhibit kynurenic acid formation via suppression of kynurenine uptake or kynurenic acid synthesis in rat brain in vitro. Springerplus. 2015 Feb 1;4:48.

[2]Di Serio C, Cozzi A, et al. Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005 Sep;25(6):981-93.

[3]Stone TW. Does kynurenic acid act on nicotinic receptors? An assessment of the evidence. J Neurochem. 2020 Mar;152(6):627-649. doi: 10.1111/jnc.14907. Epub 2019 Nov 24. PMID: 31693759; PMCID: PMC7078985.

[4]Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci. 1990 Sep;10(9):2965-73. doi: 10.1523/JNEUROSCI.10-09-02965.1990. PMID: 2168940; PMCID: PMC6570241.

[5]Marciniak S, Wnorowski A, Smolińska K, Walczyna B, Turski W, Kocki T, Paluszkiewicz P, Parada-Turska J. Kynurenic Acid Protects against Thioacetamide-Induced Liver Injury in Rats. Anal Cell Pathol (Amst). 2018 Sep 20;2018:1270483. doi: 10.1155/2018/1270483. PMID: 30327755; PMCID: PMC6171262.